December 29, 2011 — A budesonide/formoterol pressurized metered dose inhaler (pMDI) reduced chronic obstructive pulmonary disease (COPD) exacerbations more effectively than a formoterol dry powder ...
Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.
The AERISTO trial results did not affect approval but could make it harder to market the drug in a competitive market where GSK’s Anoro (umeclidinium+vilanterol) is a benchmark treatment. AZ hopes to ...
AstraZeneca will discontinue the production of PULMICORT® (budesonide) 100 and 200 µg/dose HFA pMDI (pressurised metered dose inhaler) due to complex manufacturing issues related to technical aspects ...
AstraZeneca is giving up on a hard-to-manufacture inhaler. The company will stop making Pulmicort pMDI, a form of the asthma drug delivered through a pressurized inhaler, because of "manufacturing ...
Slough, UK, June 20 th 2023: Lupin Healthcare, the UK-based wholly owned subsidiary of Lupin Limited (Lupin) has announced the UK launch of Beclu ® (beclometasone dipropionate) 100 micrograms (mcg) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results